Joosse Iris R, Mantel-Teeuwisse Aukje K, Suleman Fatima, van den Ham Hendrika A
Utrecht WHO Collaborating Centre for Pharmaceutical Policy and Regulation, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Universiteitsweg 99, 3584 CG Utrecht, The Netherlands.
WHO Collaborating Centre for Pharmaceutical Policy and Evidence Based Practice, School of Health Sciences, University of KwaZulu-Natal, Durban 4000, South Africa.
Children (Basel). 2024 Feb 20;11(3):266. doi: 10.3390/children11030266.
Monitoring access to pediatric medicines as part of the Sustainable Development Goal (SDG) agenda for 2030 requires surveying age-appropriate medicines. This study aimed to develop tracer sets of essential age-appropriate medicines for use in SDG indicator 3.b.3 or in conjunction with other methodologies for monitoring access to medicines. Two sets of medicines were developed, one for young children (1 month to 5 years) and one for school-aged children (5-12 years). Priority diseases were selected based on the global burden of disease and linked to active ingredients of first choice according to treatment guidelines and the World Health Organization (WHO) Model List of Essential Medicines for Children (EMLc). To ensure clinical relevance, the Delphi technique was employed to identify areas of (dis)agreement among clinical pediatric experts. During two consultation rounds, experts were invited to indicate (dis)agreement. Five experts per age group were largely in agreement with the initial selections, but various therapeutic alternatives were suggested for addition. A second consultation round with five experts did not lead to major adjustments. The final sets included 26 treatment options for both groups. Specific age-appropriate formulations were selected from the WHO EMLc 2023. These two globally representative tracer sets of medicines consider the particular needs of children and could aid countries in the critical monitoring of accessibility to pediatric medicines.
作为2030年可持续发展目标（SDG）议程的一部分，监测儿科药物的可及性需要对适合各年龄段的药物进行调查。本研究旨在制定适用于可持续发展目标指标3.b.3或与其他监测药物可及性方法结合使用的基本适合各年龄段药物的追踪清单。制定了两套药物清单，一套针对幼儿（1个月至5岁），另一套针对学龄儿童（5至12岁）。根据全球疾病负担选择优先疾病，并根据治疗指南和世界卫生组织（WHO）《儿童基本药物清单》（EMLc）与首选活性成分相关联。为确保临床相关性，采用德尔菲技术确定临床儿科专家之间的（不）一致领域。在两轮咨询中，邀请专家指出（不）一致之处。每个年龄组的五名专家在很大程度上同意最初的选择，但建议增加各种治疗替代方案。与五名专家进行的第二轮咨询并未导致重大调整。最终清单包括两组的26种治疗选择。从WHO 2023年EMLc中选择了特定的适合各年龄段的剂型。这两套具有全球代表性的药物追踪清单考虑了儿童的特殊需求，并可帮助各国对儿科药物的可及性进行关键监测。
